Ryogen Licenses Human Aminopeptidase P Gene Patent to OriGene Technologies

Suffern, NY, August 15, 2006 - Ryogen LLC (Ryogen) headquartered in Suffern, NY and OriGene Technologies Inc., of Rockwell, MD (OriGene) announced today that they have entered into a nonexclusive license agreement whereby OriGene has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

The US Patent No. 6,399,349 titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene that codes for the clinically important protein, membrane-bound aminopeptidase P (AmP) discovered by Dr. James Ryan in the sixties. Dr. Ryan, the Chief Scientist of Ryogen, subsequently sequenced the XPNPEP2 gene that codes for the AmP. This gene is a significant marker for hypertension, angioedema, rejection of kidney transplants, certain tumors and other diseases. This valuable patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.

"We are happy to extend a license under the AmP Patent to OriGene Technologies," said Valeria Poltorak, Ryogen's Vice President. "We look forward to working with OriGene to make this important discovery available for research applications," she concluded.

About OriGene Technologies

OriGene provides innovative technologies for large-scale gene function analyses.

OriGene's flagship product is the TrueClone Collection, a searchable source of over 30,000 human full-length cDNA clones suitable for transfection and protein expression.

More information about OriGene Technologies, the GFC-Arrays and their other products can be found at the company's web site http://www.origene.com.

About Ryogen LLC

Ryogen LLC, headquartered in Suffern, NY, is a genomic start-up and a portfolio company of IP Holdings LLC, an idea incubator also located in Suffern, NY. In addition to U.S. Patents Nos. 6,399,349 and 7,273,718, Ryogen owns an important IP portfolio pertaining to the human genome.  Those inventions are directed to genes of lipoprotein-associated phospholipase A2, Snare YKT6, glucokinase, adipocyte enhancer binding protein, POLD2 polymerase, SMS3, Phemx (TSSC6), TSSC4, HASH2, ribosomal protein L26, MDM2, carboxypeptidase D, carboxypeptidase M, RhoC, retinol binding protein, resistin, syntaxin and the CD81 antigen.

For further information on Ryogen contact Valeria Poltorak, Ryogen LLC, Montebello Park, 75 Montebello Road, Suffern, NY 10901; telephone: (845) 368-4000 x111; or e-mail: valeria@ryogen.com.

About IP Holdings LLC

IP Holdings LLC is an idea incubator with a focus on patent commercialization. For further information on IP Holdings contact IP Holdings LLC, Montebello Park, 75 Montebello Road, Suffern, NY 10901; telephone: (845) 368-4000; e-mail: info@ip-holdings.com or visit www.ip-holdings.com.